02 Increasing Prevalence of Genetic Disorders The rising global prevalence of genetic disorders and complex diseases highlights the significance of SNP genotyping in understanding disease etiology, genetic susceptibility, and disease progression. Genome-wide association studies (GWAS) use SNP genotyping data to identify genetic variants associated with cancer, cardiovascular disease, autoimmune disorders, and neurological disorders, increasing demand for genotyping services and platforms. According to the World Health Organization (WHO), genetic disorders contribute significantly to the global disease burden, affecting millions of people and families. According to the CDC, genetic disorders and congenital abnormalities affect approximately 2%-5% of all live births. They are also responsible for 20-30% of infant deaths.Furthermore, cystic fibrosis, sickle cell disease, Huntington's disease, and hereditary cancers are all well-documented conditions caused by pathogenic genetic variants. The prevalence of genetic disorders varies greatly across populations and geographic regions, owing to genetic diversity, consanguinity rates, and environmental exposure. China has the world's highest prevalence of rare genetic diseases, with over 10 million people affected by chromosome disease syndromes and over 1 million by monogenic diseases. As of the end of September 2023, China had registered approximately 780,000 rare disease cases. In India, more than 1.7 million children are born with congenital disabilities each year.As a result, the rising prevalence of genetic disorders emphasizes the significance of SNP genotyping in understanding disease etiology, identifying disease-associated genetic variants, and guiding personalized healthcare interventions. Researchers and clinicians can use genotyping technologies to improve diagnostic accuracy, optimize treatment strategies, and improve patient outcomes in managing genetic disorders.
04 High Cost of Genotyping Platforms and Assays The initial investment required to acquire SNP genotyping platforms, instruments, and reagents can be significant, especially for high-throughput systems and advanced technologies like next-generation sequencing (NGS). Furthermore, the recurring costs of consumables, maintenance, and data analysis software can strain the budgets of research laboratories, academic institutions, and clinical facilities, limiting the adoption and accessibility of genotyping technologies, particularly in resource-constrained environments.Moreover, the cost of genotyping platforms varies depending on the technology used (e.g., microarray-based, PCR-based, sequencing-based), throughput capacity, and level of automation. High-throughput systems processing thousands to millions of SNP markers at once typically have higher initial costs than low-throughput or manual methods. For example, SNP assays cost between USD 200 and USD 375 and can handle up to 1500 samples. There is also a volume-dependent charge that begins at USD 0.85 for each requested genotype.Hence, the high cost of genotyping platforms and assays may discourage smaller research laboratories, academic institutions, and resource-constrained settings from implementing SNP genotyping technologies, limiting access to genomic analysis capabilities. Furthermore, advances in multiplexing technologies, assay miniaturization, and lab automation aim to lower per-sample costs and increase throughput efficiency, making genotyping technologies more accessible and cost-effective for various applications and end users.
01 Expansion of Personalized Medicine As understanding the genetic basis of diseases advances, there is a growing interest in personalized medicine approaches that use SNP genotyping data to tailor treatments to individual patients. Incorporating genotyping technologies into clinical practice allows healthcare providers to identify genetic variants associated with drug response, disease risk, and treatment outcomes, allowing for more targeted and effective therapeutic interventions. Genotyping providers can collaborate with healthcare institutions, pharmaceutical companies, and regulatory agencies to advance personalized medicine and improve patient outcomes. In November 2022, for example, the Cleveland Clinic expanded its cutting-edge genetic testing platform for cancer patients, making it the standard treatment option. Whole-exome sequencing, which examines all other genome regions, has increased the ability to analyze genomic content in tumor tissue samples.In 2023, the first CRISPR-based gene-editing therapy was approved. Gene editing can remove, insert, or modify parts of our genetic code. Advances in genomics, including SNP genotyping technologies, have fueled the growth of personalized medicine approaches, allowing healthcare providers to identify genetic variants linked to disease susceptibility, drug response, and treatment outcomes. Genome-wide association studies (GWAS) use SNP genotyping data to identify genetic markers associated with complex diseases, which aids in developing targeted therapies and precision medicine interventions.
June 2026 Thermo Fisher Scientific expanded its genomic analysis portfolio by introducing advanced SNP genotyping workflows integrated with high-throughput sequencing and cloud-based bioinformatics solutions to accelerate precision medicine and genetic research.
April 2026 Illumina, Inc. strengthened its genotyping portfolio by expanding collaborations with global research institutions to support large-scale population genomics and precision medicine studies using high-density SNP arrays.
February 2026 QIAGEN N.V. expanded its molecular diagnostics portfolio by introducing enhanced PCR-based SNP genotyping assays and automated data analysis tools for clinical and research laboratories.
January 2026 Agilent Technologies expanded its genomics solutions through new automation capabilities supporting high-throughput SNP genotyping and biomarker discovery workflows.
October 2025 Standard BioTools Inc. (formerly Fluidigm) launched enhanced SNP genotyping solutions featuring improved multiplexing capabilities for agricultural genomics, clinical research, and translational medicine applications.